



IMPROVEMENT OF PATIENT OUTCOMES WITH HEMOGLOBIN MONITORING

Aryeh Shander, MD, FCCM, FCCP, FASA
Director, TeamHealth Research Institute

Emeritus Chief Department of Anesthesiology, Critical Care and Hyperbaric Medicine
Englewood Hospital and Medical Center, Englewood, New Jersey

Courtesy Clinical Professor UF College of Medicine

Adjunct Clinical Professor of Anesthesiology, Medicine and Surgery
Icahn School of Medicine at Mount Sinai, New York

Clinical Professor of Anesthesiology Rutgers Medical School, New Jersey



DISCLOSURE 1

SPEAKERS BUREAU: Merck

CONSULTANT/SPEAKER: Masimo Corporation, CSL Behring, Gauss Surgical, Vifor Pharma, Octapharma and Pharmaniaga


GRANT/RESEARCH: CSL Behring, Masimo, HbO2 Therapeutics, LLC

DISCLOSURE 2

CONSULTANT: USDOD, USDOJ AND USDHHS

OVERVIEW

- What is PBM and why in the ICU?
- Treating numbers vs. patients
- Prevalence of anemia in ICU
- Consequences of anemia, transfusions
- Anemia causes (Etiology in critically ill patients)
- “New” concept of iatrogenic anemia (SpHb)
- Applying PBM in the ICU





The mission of *Choosing Wisely* is to promote conversations between clinicians and patients by helping patients choose care that is:


- Supported by evidence
- Not duplicative of other tests or procedures already received
- Free from harm
- Truly necessary

SABM DEFINITION OF PBM

“The timely application of evidence based medical and surgical concepts designed to manage anemia, optimize hemostasis, and minimize blood loss in order to improve patient outcomes.”

*Patient focused – Medical
condition (disease) focused*

PATIENT BLOOD MANAGEMENT




PREVALENCE OF ANEMIA IN THE CRITICALLY ILL

- Sakr et al reported anemia in the ICU - 18.7% had Hb <7 g/dL and 29.5% had 7-9 g/dL¹
- Cardenas-Turanzas et al reported an incidence of 46.6% and prevalence of 68% of anemia in cancer patients admitted to ICU²
- Thomas et al reported that 98 of 100 consecutive patients admitted to ICU were anemic³
- Anemia was associated with increased risk of allogeneic blood transfusion¹
- Higher Hb level was independently associated with lower risk of in-hospital death¹

1. Sakr Y et al. Crit Care 2010
2. Cardenas-Turanzas M et al. J Crit Care 2010
3. Thomas J et al. Heart Lung 2010

WHO DEFINITION OF ANEMIA VS Hb DISTRIBUTION IN GENERAL POPULATION



1. World Health Organization. Geneva, Switzerland; 2001.
2. Dallman PR, et al. In: Iron Nutrition in Health and Disease London, UK: John Libbey & Co; 1996:65-74.


Haematocrit is invalid for estimating red cell volume: a prospective study in male volunteers

Matthias Jacob¹, Simon Annaheim², Urs Boutellier², Christian Hinske¹, Markus Rehm¹, Christian Breymann³, Alexander Krafft³


- N = 46 healthy male endurance athletes
- Red cell volume ($2,282 \pm 283$ mL) did not correlate with either hct (0.42 ± 0.02) or hb conc (14.2 ± 0.8 , $P > 0.05$, resp.)
- RCV was predictable from body surface area ($P < 0.01$)
- A similar accuracy was unobtainable using any potential predictor for plasma or blood volume, hct or hb concentration
- RCV showed high intra-individual stability when measured again after 4 weeks, whereas plasma volume oscillated in both directions by up to 22%

Hemoglobin is a concentration measure – meaningless alone

RED CELL MASS VS. HEMOGLOBIN CONCENTRATION




MALE




FEMALE

NORMAL RED CELL MASS



REDUCED RED CELL MASS



	Recommendations
NIH Consensus Conference, ⁴² 1988	<70 g/L (acute)
American College of Physicians, ⁴³ 1992	No number
American Society of Anesthesiologists, ⁴⁴ 1996	<60 g/L (acute)
American Society of Anesthesiologists, ⁴⁵ 2006	No number
Canadian Medical Association, ⁴⁶ 1997	No number
Canadian Medical Association, ⁴⁶ 1998	No number
College of American Pathologists, ⁴⁷ 1998	60 g/L (acute)
British Committee for Standards in Haematology, ⁴⁸ 2001	No number
British Committee for Standards in Haematology, ⁴⁹ 2012	70 g/L*
Australasian Society of Blood Transfusion, ⁵⁰ 2001	70 g/L
Society for Thoracic Surgeons, Society of Cardiovascular Anesthesiology, ⁵¹ 2007	70 g/L
Society for Thoracic Surgeons, Society of Cardiovascular Anesthesiology, ⁵² 2011	80 g/L*
American College of Critical Care Medicine, Society of Critical Care Medicine, ⁵³ 2009	70 g/L
American College of Critical Care Medicine, Society of Critical Care Medicine, ⁵⁴ 2009	70 g/L
Society for the Advancement of Blood Management, ⁵⁵ 2011	80 g/L
National Blood Authority, Australia, ⁵³ 2012	No number
AABB, ⁵⁶ 2012	70–80 g/L or 80 g/L†
Kidney Disease: Improving Global Outcomes, ⁵⁷ 2012	No number
National Cancer Center Network, ⁵⁸ 2012	70 g/L

*For patients with acute blood loss. †For patients with symptoms of end-organ ischaemia.

GUIDELINES**Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology***First update 2016*

Sibylle A. Kozek-Langeneck,
Guidrius Barauskas, Edoard
Thorsten Haas, Matthias Jac
Jens Meier, Zsolt L. Molnar,
Philippe J.F. Van der Linden,

1.3.1. Transfusion triggers

We recommend a target haemoglobin concentration of 7 to 9 g dl⁻¹ during active bleeding. **1C**



Continuous haemoglobin monitoring can be used as a trend monitor. **C**



SpHb



PVI

RELATIONSHIP OF PVI AND SpHb




 SpHb

 PVI




BLEEDING IN SURGERY



POST-SURGICAL: CARDIAC ICU

Case Example




RED BLOOD CELL TRANSFUSION IN ADULT TRAUMA AND CRITICAL CARE

- Recommendations Regarding RBC Transfusion in Patients With Neurologic Injury and Diseases
 - ✓ **Level 1**
 - There are insufficient data to support level I recommendations on this topic.
 - ✓ **Level 2**
 - There is no benefit of a “liberal” transfusion strategy (transfusion when Hb < 10 g/dL) in patients with moderate to severe traumatic brain injury.
 - ✓ **Level 3**
 - Decisions regarding blood transfusion in patients with subarachnoid hemorrhage must **be assessed individually because optimal transfusion triggers are not known** and there is no clear evidence that blood transfusion is associated with improved outcome.

Physicians' lack of knowledge - a possible reason for red blood cell transfusion overuse?



Roni Rahav Koren^{1,3*} , Celia Suriu^{1,2}, Orly Yakir^{1,2}, Luiza Akria^{1,2}, Masad Barhoum^{1,2†} and Andrei Braester^{1,2†}




Fig. 1 Scores of the overall questionnaire. Distribution of the overall knowledge scores of the study population. Mean overall knowledge score of the population study was 47.8 ± 18.6

Overall
average
knowledge
score: 47.8

From Tolerating Anemia to Treating Anemia

Transfusion trials undoubtedly have transformed our view of the role of allogeneic blood in patient care, leading to a welcome shift toward reduced use of allogeneic red blood cell (RBC) transfusion. Nonetheless, this change arguably has also given rise to unintended consequences. As the name implies, a transfusion trial stays focused on comparing different transfusion strategies while placing the alternatives for managing anemia on the so-called back burner (1).

The NEW ENGLAND
JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

OCTOBER 9, 2014

VOL. 371 NO. 15

Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock

Lars B. Holst, M.D., Nicolai Haase, M.D., Ph.D., Jørn Wetterslev, M.D., Ph.D., Jan Wernerman, M.D., Ph.D.,
Anne B. Guttormsen, M.D., Ph.D., Sari Karlsson, M.D., Ph.D., Pär I. Johansson, M.D., Ph.D.,
Anders Åneman, M.D., Ph.D., Marianne L. Vang, M.D., Robert Winding, M.D., Lars Nebrich, M.D.,
Helle L. Nibro, M.D., Ph.D., Bodil S. Rasmussen, M.D., Ph.D., Johnny R.M. Lauridsen, M.D., Jane S. Nielsen, M.D.,
Anders Oldner, M.D., Ph.D., Ville Pettilä, M.D., Ph.D., Maria B. Cronhjort, M.D., Lasse H. Andersen, M.D.,
Ulf G. Pedersen M.D., Nanna Reiter, M.D., Jørgen Wiis, M.D., Jonathan O. White, M.D., Lene Russell, M.D.,
Klaus J. Thornberg, M.D., Peter B. Hjortrup, M.D., Rasmus G. Müller, M.D., Morten H. Møller, M.D., Ph.D.,
Morten Steensen, M.D., Inga Tjäder, M.D., Ph.D., Kristina Kilsand, R.N., Suzanne Odeberg-Wernerman, M.D., Ph.D.,
Brit Sjøbø, R.N., Helle Bundgaard, M.D., Ph.D., Maria A. Thyø, M.D., David Lodahl, M.D., Rikke Mærkedahl, M.D.,
Carsten Albeck, M.D., Dorte Illum, M.D., Mary Kruse, M.D., Per Winkel, M.D., D.M.Sci.,
and Anders Perner, M.D., Ph.D., for the TRISS Trial Group* and the Scandinavian Critical Care Trials Group

TRISS Trial


PRIMARY AND SECONDARY OUTCOME MEASURES

Outcome	Lower Hemoglobin Threshold	Higher Hemoglobin Threshold	Relative Risk (95% CI)	P Value
Primary outcome: death by day 90 — no./total no. (%)	216/502 (43.0)	223/496 (45.0)		0.44†
Secondary outcomes‡				
Use of life support — no./total no. (%)§				
At day 5	278/432 (64.4)	284/432 (65.8)	1.04 (0.93–1.14)	0.47†
At day 14	140/380 (36.8)	140/380 (36.8)	0.99 (0.81–1.19)	0.95†
At day 28	104/322 (32.3)	104/322 (32.3)	0.77 (0.54–1.09)	0.14†
Ischemic event in the ICU — no./total no. (%)¶		39/489 (8.0)	0.90 (0.58–1.39)	0.64
Severe adverse reaction — no./total no.		1/489 (0.2)	—	1.00
Alive without vasopressor or inotropic support — mean % of days††	73	75	—	0.93
Alive without mechanical ventilation — mean % of days††	65	67	—	0.49
Alive without renal replacement therapy — mean % of days††	85	83	—	0.54
Alive without any of the above — mean % of days††	30	31	—	0.89

More Than 10-20 Times Normal

GENE TRANSFER

Quantitative allele-specific PCR




GENE TRANSFER WITH TRANSFUSION

Nevada man's DNA changes after bone marrow transplant and is replaced by that of his German donor following treatment for leukemia

Transfusion of Red Blood Cells, Fresh Frozen Plasma, or Platelets and the Risk of Infection and Death

Yi Li



Plate

TRANSFUSION AS THERAPY


Blood Shield Laws

- Blood is “unavoidably unsafe”
- Blood is “inherently dangerous”

Preoperative anemia versus blood transfusion: Which is the culprit for worse outcomes in cardiac surgery?

 Check for updates

Damien J. LaPar, MD, MSc,^a Robert B. Hawkins, MD, MSc,^a Timothy L. McMurry, PhD,^a
 James M. Iqbal, MD, MSc,^a Jeffrey P. Rich, MD,^b Alan M. Speir, MD,^c Mohammed A. Ouader, MD,^d






Don't transfuse more units of blood than absolutely necessary.

Each unit of blood carries risks. A restrictive threshold (7.0-8.0g/dL) should be used for the vast majority of hospitalized, stable patients without evidence of inadequate tissue oxygenation (evidence supports a threshold of 8.0g/dL in patients with pre-existing cardiovascular disease). Transfusion decisions should be influenced by symptoms and hemoglobin concentration. Single unit red cell transfusions should be the standard for non-bleeding, hospitalized patients. Additional units should only be prescribed after re-assessment of the patient and their hemoglobin value.

MAZER VS. MURPHY

- Looking beyond txn as the “only treatment option”
 - What is the medical condition to diagnose here?
 - Are we managing that medical condition properly?



Blood transfusion: one unit too much or one unit +
which strategy poses the smallest risk to the

E. Seifried & M. M. Mueller

The best transfusion strategy and optimal dosing for packed red blood cells are still missing. Best indications. Sufficiently powered, prospective, randomized, controlled clinical transfusion trials for packed red blood cells in most clinical settings are urgently needed to reduce ill-founded clinical decisions and to base transfusion strategies on clinical evidence and scientific study results.

PREVALENCE OF IRON DEFICIENCY ANEMIA

- Walsh TS et al. - 35% of patients have red cell indices consistent with functional iron deficiency at ICU admission¹
- Lasocki S et al. Iron deficiency may affect up to 40% of critically ill patients ²
- Rodriguez RM et. al. 9% of ICU patients were iron deficient, 2% B12 deficient, and 2% folic acid deficient³

1. Walsh TS. Br J Anaesth. 2006
2. Lasocki S. Anesthesiology, 2011
3. Rodriguez RM . J Crit Care. 2001

Prevalence of iron deficiency on ICU discharge and its relation with fatigue: a multicenter prospective study

Sigismond Lasocki^{1,6*}, Nicolas Chudeau¹, Thibaut Papet², Deborah Tartiere³, Antoine Roquilly⁴, Laurence Carlier¹, Olivier Mimoz², Philippe Seguin³, Yannick Malledant³, Karim Asehnoune⁴, Jean François Hamel⁵ and for the AtlanREA group

- The prevalence of ID was approximately 10% on ICU discharge
- The prevalence of ID increased to 35% at 6 months
- A quarter of the critically ill patients were still anemic at 6 months
- ID was associated with increased fatigue 1 month after ICU discharge, independently of low Hb levels

ANEMIA PREVALENCE




Fig. 1 Prevalence of anaemia. Prevalence of anaemia worldwide and in patients at high risk. Figure based on [6]



2

Don't transfuse red blood cells for iron deficiency without hemodynamic instability.

Blood transfusion has become a routine medical response despite cheaper and safer alternatives in some settings. Pre-operative patients with iron deficiency and patients with chronic iron deficiency without hemodynamic instability (even with low hemoglobin levels) should be given oral and/or intravenous iron.

Anemia in Critical Illness

Insights into Etiology, Consequences, and Management

Shailaja J. Hayden¹, Tyler J. Albert^{1,2}, Timothy R. Watkins^{1,3}, and Erik R. Swenson^{1,2}

- Anemia is highly prevalent in the critically ill
- It is associated with higher health care resource use
- Associated with poor patient outcomes
- Further research should delineate risks, benefits, and effectiveness of various management strategies in specific patient populations rather than transfusion triggers

ETIOLOGY OF ANEMIA IN THE CRITICALLY ILL

- Diagnostic phlebotomy (~ 750-900 mL/ICU stay)
 - Range 40-80 mL/day
 - Accounts for 20% of total blood loss
- Occult and overt bleeding: wounds, drains & GI tract
- Anemia due to underproduction*
 - Blunted erythropoietin response to low Hct
 - Cytokines (IL-1b, TNF-a) inhibit erythropoietin gene
 - Inflammatory processes in the ICU - **Hepcidin**
 - **Altered iron metabolism**
 - Impaired proliferation and differentiation of erythroid progenitors
- **Hemodilution?**

**“THERE IS NO REMEDY IN THE WORLD WHICH
WORKS AS MANY MIRACLES AS BLEEDING.”**

Guy Patin 1645

PHLEBOTOMY IN ICU AND NON ICU PATIENTS


- 50 ward patients, 50 all or part of hospitalization in ICU
- **Ward** - samples 1.1/day, mean **12.4 ml/day**, 175 ml
- **ICU** - samples 3.4/day, mean **41.5 ml/day**, 762 ml
- If had a-line more blood draws and more blood drawn
- **56% ICU patients transfused vs 16% Ward patients**
- 50% of transfused had phlebotomy > 180 ml

PHLEBOTOMY

- “In today’s medicine blood letting continues ... unabated. We have refined the technique, call it ‘lab work’ jab the patient incessantly, generate reams of questionable data ...”

UNNECESSARY LAB TESTS

- Information theory to identify redundancy in common lab tests



REDUCING PHLEBOTOMY


- Strategy
 - Low volume blood tubes
 - Standardization of blood collection from central lines
 - POC glucose testing
- Average daily blood loss reduction per ICU patient of 10 ml
- Reduction of RBC transfusion of 15%

Twenty-five million liters of blood into the sewer

M. LEVI

- Current collection methods and the small amounts of blood or serum required by modern laboratory analyzers:
 - Each 25 million liter of patients' blood is thrown into waste containers
- 4 times more than the total volume of blood that is transfused each year
- Patients develop 'HAA' due to blood collection
 - Associated with an adverse outcome
- Collection methods - adapted to the much smaller volumes required by new generation laboratory analyzers
 - Especially for hematology or oncology patients, critically ill patients, or children

LAB Hb: INTERMITTENT & DELAYED RESULTS TRANSFUSION DECISIONS MADE IN REAL TIME






SpHb

Continuous Noninvasive Hemoglobin Monitoring: A Measured Response to a Critical Review

Steven J. Barker, PhD, MD,* Aryeh Shander, MD,†‡ and Michael A. Ramsay, MD§

SpHb and Bleeding: An example



Accurate to 1 cm

Accurate to 1 meter



Which one is preferred?
Accuracy over reliability?

Journal of Clinical Monitoring and Computing 2016 end of year summary: cardiovascular and hemodynamic monitoring

Bernd Saugel¹ · Karim Bendjelid² · Lester A. Critchley³ · Steffen Rex⁴ · Thomas W. L. Scheeren⁵

9 Hemodynamic monitoring: impact on patient outcome and clinical decision-making

As hemodynamic monitoring can only improve patient outcome if coupled with therapeutic interventions the JCMC welcomes studies investigating the impact of hemodynamic management on clinical decision-making and outcome.



4

Don't perform serial blood counts on clinically stable patients.

Transfusion of red blood cells or platelets should be based on the first laboratory value of the day unless the patient is bleeding or otherwise unstable. Multiple blood draws to recheck whether a patient's parameter has fallen below the transfusion threshold (or unnecessary blood draws for other laboratory tests) can lead to excessive phlebotomy and unnecessary transfusions.

PHLEBOTOMY TEST TUBES



CLINICAL STRATEGIES TREATING ANEMIA

- Early identification & treatment of anemia before reaching a “Transfusion Threshold (TRIGGER)”
- Avoid daily blood draws unless absolutely needed
- Use of other treatments before allogeneic blood
 - ESA
- Nutritional supplements
 - **Iron and possible hepcidin antagonists**
 - Folic Acid
 - B₁₂
- Bleeding and BM failure, directed therapy

Transfusion Medicine Reviews 31 (2017) 264–271



ELSEVIER

Contents lists available at ScienceDirect

Transfusion Medicine Reviews

journal homepage: www.tmreviews.com




Patient Blood Management in the Intensive Care Unit

Aryeh Shander*, Mazyar Javidroozi, Gregg Lobel

Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center and TeamHealth Research Institute, Englewood, NJ



THE FREQUENCY OF BLOOD SAMPLES (LEFT) TO



OF DIAGNOSTIC FREQUENCY (RIGHT) AND AFTER THE IMPLEMENTATION OF PBM

EDITORIAL

Open Access

Iatrogenic hemodilution: a possible cause for avoidable blood transfusions?



Azriel Perel 

Continuous Noninvasive Hemoglobin Monitoring

Re
Aft

Şerba
Eugel
and A

40 pat
patien




Figure 2. A, A scatter plot of 132 paired measurements as determined by BHB and by SpHb. SpHb and BHB are expressed as g/dL. The correlation coefficient (r) was 0.58, and the 95% confidence interval was 0.46–0.68. B, Corrected Bland–Altman plot for repeated measurements of 132 paired hemoglobin values as determined by BHB and by SpHb. The dashed black line represents the mean bias ($-0.3 \text{ g}\cdot\text{dL}^{-1}$), the dashed blue lines represent 1 SD ($1.5 \text{ g}\cdot\text{dL}^{-1}$), and the continuous black lines represent the LOA (-2.7 to $3.3 \text{ g}\cdot\text{dL}^{-1}$). BHB indicates laboratory hemoglobin; LOA, limit of agreement; SD, standard deviation; SpHb, continuous noninvasive hemoglobin.

Patient Blood Management
What Else ?

TABLE 1. Benefits of Patient Blood Management

	Change	<i>P</i>	Number of Patients
--	--------	----------	--------------------

Now that safety and efficacy of patient blood management has systematically been confirmed by this meta-analysis, the stage is set for worldwide implementation. Conversely, not implementing patient blood management represents substandard care.

LOS indicates length of stay.

Patient blood management is not about blood transfusion: it is about patients' outcome

 BLOOD
TRANSFUSION

Thomas Frietsch^{1,2}, Aryeh Shander^{3,4}, David Faraoni^{5,6}, Jean-Francois Hardy^{7,2}

¹Interdisciplinary Task Force for Clinical Haemotherapy (IAKH), Marburg, Germany; ²Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis (NATA), Paris, France; ³Icahn School of Medicine, Mount Sinai Hospital, New York, NY, United States of America; ⁴TeamHealth Research Institute, West Palm Beach, FL, United States of America; ⁵Department of Anaesthesiology, Division of Cardiac Anaesthesia, The Hospital for Sick Children, Toronto, ON, Canada; ⁶Department of Anaesthesia and Pain Medicine, University of Toronto, ON, Canada; ⁷Department of Anaesthesiology and Pain Medicine, University of Montreal, Montreal, QC, Canada

We have sincere concerns that the organizers of the conference (i.e. blood establishment) might (should) not be in the best position to publish recommendations for the use of their "products" free of conflicts of interest.

SUMMARY

- Why PBM in the ICU?
- Prevalence of anemia in ICU
- Consequences of anemia
- Anemia causes (Etiology in critically ill patients)
- “New” concept of iatrogenic anemia
- Hemoglobin: Treating numbers vs. patients
- Hemoglobin monitoring
- The long-debated issue of accuracy
- Incorporating SpHb as part of PBM in the ICU

**FOR MORE INFORMATION,
GO TO: [SABM.ORG](https://www.sabm.org)**